The intricate metabolism of pancreatic cancers
F Camelo, A Le - The Heterogeneity of Cancer Metabolism, 2018 - Springer
Currently, approximately 95% of pancreatic cancers are pancreatic ductal adenocarcinoma
(PDAC), which is the most aggressive form and the fourth leading cause of cancer death …
(PDAC), which is the most aggressive form and the fourth leading cause of cancer death …
A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer
Introduction Metabolomics is an emerging approach for early detection of cancer. Along with
the development of metabolomics, high-throughput technologies and statistical learning, the …
the development of metabolomics, high-throughput technologies and statistical learning, the …
TGFβ drives metabolic perturbations during epithelial mesenchymal transition in pancreatic cancer: TGFβ induced EMT in PDAC
Simple Summary Pancreatic cancer is an aggressive disease with most patients diagnosed
at late stages resulting in poor outcomes. While it is known that pancreatic tumor cells …
at late stages resulting in poor outcomes. While it is known that pancreatic tumor cells …
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease characterized by
a diverse tumor microenvironment. The heterogeneous cellular composition of PDAC makes …
a diverse tumor microenvironment. The heterogeneous cellular composition of PDAC makes …
Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer
JM Karasinska, JT Topham, SE Kalloger, GH Jang… - Clinical Cancer …, 2020 - AACR
Purpose: Identification of clinically actionable molecular subtypes of pancreatic ductal
adenocarcinoma (PDAC) is key to improving patient outcome. Intertumoral metabolic …
adenocarcinoma (PDAC) is key to improving patient outcome. Intertumoral metabolic …
SLC7A11 and the glutathione pathway as novel prognostic markers in resectable pancreatic ductal adenocarcinoma: a metabolomics study of clinical specimens
Abstract Background/Objectives Despite the poor prognosis associated with pancreatic
ductal adenocarcinoma (PDAC), there remains a lack of clarity regarding the metabolic …
ductal adenocarcinoma (PDAC), there remains a lack of clarity regarding the metabolic …
Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer
G Zhang, P He, H Tan, A Budhu, J Gaedcke… - Clinical cancer …, 2013 - AACR
Purpose: To identify metabolic pathways that are perturbed in pancreatic ductal
adenocarcinoma (PDAC), we investigated gene-metabolite networks with integration of …
adenocarcinoma (PDAC), we investigated gene-metabolite networks with integration of …
Distinct serum metabolomics profiles associated with malignant progression in the KrasG12Dmouse model of pancreatic ductal adenocarcinoma
JJ LaConti, EC Laiakis, AD Mays, I Peran, SE Kim… - BMC genomics, 2015 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer deaths worldwide with less than a 6% 5-year survival rate. PDAC is associated with …
cancer deaths worldwide with less than a 6% 5-year survival rate. PDAC is associated with …
Employing metabolism to improve the diagnosis and treatment of pancreatic cancer
CJ Halbrook, CA Lyssiotis - Cancer cell, 2017 - cell.com
Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of
cancer-related death. The high mortality rate results from a lack of methods for early …
cancer-related death. The high mortality rate results from a lack of methods for early …
A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer
Background We applied a training and testing approach to develop and validate a plasma
metabolite panel for the detection of early-stage pancreatic ductal adenocarcinoma (PDAC) …
metabolite panel for the detection of early-stage pancreatic ductal adenocarcinoma (PDAC) …